Skip to main content
Erschienen in: Pathology & Oncology Research 4/2009

01.12.2009 | Original Paper

An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1

verfasst von: Zsuzsanna Pap, Zoltán Pávai, Lóránd Dénes, Ilona Kovalszky, János Jung

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

It is thought that dysregulation of E-cadherin, syndecan-1 (CD138) and Ets-1 is involved in carcinoma development. E-cadherin is an important epithelial cell adhesion molecule; syndecan-1 (CD138) is a regulatory proteoglycan in both cell-cell and cell-matrix adhesion and Ets-1 is a proto-oncogene and transcription factor, which takes part in extracellular matrix remodeling. Our goal was to study the changes in the expression of these molecules during colon carcinoma development and progression. We tested 117 colon adenomas and 149 de novo and ex adenoma carcinomas of the colon, using the Ultravision Polymer system. The positive reaction rate was 100% for E-cadherin, 98.3% for syndecan-1 and 22.4% for Ets-1 in adenomas, while in carcinomas it was 88.5%, 62.4% and 56.3% respectively. We found decreasing expression of E-cadherin and syndecan-1 throughout colon carcinoma progression and an opposite regulation for the Ets-1 protein. Decrease in expression of syndecan-1 is more pronounced in carcinomas compared to E-cadherin. De novo carcinomas have lower E-cadherin and syndecan-1 expression, and higher Ets-1 expression compared to ex adenoma carcinomas. These findings support the hypothesis that there are differences in the carcinogenesis of these tumors.
Literatur
1.
Zurück zum Zitat Vãlean S, Mircea PA, Oprea L (2006) Trends of mortality rates from gastric cancer and colorectal cancer in Romania, 1955–2003. J Gastrointestin Liver Dis 15(2):111–115PubMed Vãlean S, Mircea PA, Oprea L (2006) Trends of mortality rates from gastric cancer and colorectal cancer in Romania, 1955–2003. J Gastrointestin Liver Dis 15(2):111–115PubMed
2.
Zurück zum Zitat Hamilton RS, Aaltonen AL (2000) Pathology and genetics, toumors of the digestive system. IARC Press, Lyon Hamilton RS, Aaltonen AL (2000) Pathology and genetics, toumors of the digestive system. IARC Press, Lyon
3.
Zurück zum Zitat Pećina-Šlaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17PubMed Pećina-Šlaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17PubMed
4.
Zurück zum Zitat Day MR, Hao X, Mohammad I, Daszak P, Talbot IC, Forbes A (1999) Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 434:121–125CrossRefPubMed Day MR, Hao X, Mohammad I, Daszak P, Talbot IC, Forbes A (1999) Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 434:121–125CrossRefPubMed
6.
Zurück zum Zitat Nakayama T, Masahiro I, Akira O, Shinji N, Ichiro S (2001) Expression of the ets-1 Proto-Oncogene in human colorectal carcinoma. Mod Pathol 14(5):415–422CrossRefPubMed Nakayama T, Masahiro I, Akira O, Shinji N, Ichiro S (2001) Expression of the ets-1 Proto-Oncogene in human colorectal carcinoma. Mod Pathol 14(5):415–422CrossRefPubMed
7.
Zurück zum Zitat Arun S, Watson KD (2005) Ets transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462–2478 Arun S, Watson KD (2005) Ets transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462–2478
8.
Zurück zum Zitat Nosho K, Yoshiday M, Yamamoto M, Taniguchi H, Adachi Y, Mikami M, Hinodal Y, Imai K (2005) Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26(5):892–899CrossRefPubMed Nosho K, Yoshiday M, Yamamoto M, Taniguchi H, Adachi Y, Mikami M, Hinodal Y, Imai K (2005) Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26(5):892–899CrossRefPubMed
9.
Zurück zum Zitat Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A, Wernert N (2003) Stromal expression of invasion-promoting matrix-degrading proteases MMP-1 and -9 and the Ets-1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 107:183–188CrossRefPubMed Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A, Wernert N (2003) Stromal expression of invasion-promoting matrix-degrading proteases MMP-1 and -9 and the Ets-1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 107:183–188CrossRefPubMed
10.
Zurück zum Zitat Khoursheed MA, Mathew TC, Makar RR, Louis S, Asfar SK, Al-Sayer HM, Dashti HM, Al-Bader A (2003) Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel 86–91 Khoursheed MA, Mathew TC, Makar RR, Louis S, Asfar SK, Al-Sayer HM, Dashti HM, Al-Bader A (2003) Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel 86–91
11.
Zurück zum Zitat Elzagheid A, Ålgars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S (2006) E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol 12(27):4304–4309PubMed Elzagheid A, Ålgars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S (2006) E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol 12(27):4304–4309PubMed
12.
Zurück zum Zitat Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J Cancer Res 192:1074–1081 Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J Cancer Res 192:1074–1081
13.
Zurück zum Zitat Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP, Haglund C (2005) Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68:306–313CrossRefPubMed Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP, Haglund C (2005) Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68:306–313CrossRefPubMed
14.
Zurück zum Zitat Rosai J (2004) Rosai and Ackerman`s surgical pathology, 9th edn. Mosby, London Rosai J (2004) Rosai and Ackerman`s surgical pathology, 9th edn. Mosby, London
15.
Zurück zum Zitat Geller SA, Dhall D, Alsabeh R (2008) Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med 132:490–499PubMed Geller SA, Dhall D, Alsabeh R (2008) Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med 132:490–499PubMed
16.
Zurück zum Zitat Wlodarczyk J, Bethke B, Mueller E, Stolte M, Mueller J (2001) A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum. Virchows Arch 439:756–761PubMed Wlodarczyk J, Bethke B, Mueller E, Stolte M, Mueller J (2001) A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum. Virchows Arch 439:756–761PubMed
17.
Zurück zum Zitat Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K (2006) Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch 448:763–767CrossRefPubMed Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K (2006) Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch 448:763–767CrossRefPubMed
18.
Zurück zum Zitat Peretti T, Waisberg J, Mader AM, Matos L, Costa R, Conceicao G, Lopes A, Nader H, Pinhal M (2008) Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol & Hepatol 20:756–765CrossRef Peretti T, Waisberg J, Mader AM, Matos L, Costa R, Conceicao G, Lopes A, Nader H, Pinhal M (2008) Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol & Hepatol 20:756–765CrossRef
19.
Zurück zum Zitat Gottardi JC, Wong E, Gumbiner MB (2001) E-Cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 153(5):1049–1059CrossRefPubMed Gottardi JC, Wong E, Gumbiner MB (2001) E-Cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 153(5):1049–1059CrossRefPubMed
20.
Zurück zum Zitat Qinglang L, Pyong WP, Wilson LC, Parks CW (2002) Matrilysin shedding of syndecan-1 regulates Chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635–646CrossRef Qinglang L, Pyong WP, Wilson LC, Parks CW (2002) Matrilysin shedding of syndecan-1 regulates Chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635–646CrossRef
21.
Zurück zum Zitat Fitzgerald LM, Wang Z, Park WP, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol 148(4):811–824CrossRefPubMed Fitzgerald LM, Wang Z, Park WP, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol 148(4):811–824CrossRefPubMed
22.
Zurück zum Zitat Hashimoto Y, Skacel M, Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8(185):1–7 Hashimoto Y, Skacel M, Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8(185):1–7
23.
Zurück zum Zitat Kwak JM, Min BW, Lee JH, Choi JS, Lee SI, Park SS, Kim J, Um JW, Kim SH, Moon HY (2007) The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum 50:1873–1880CrossRefPubMed Kwak JM, Min BW, Lee JH, Choi JS, Lee SI, Park SS, Kim J, Um JW, Kim SH, Moon HY (2007) The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum 50:1873–1880CrossRefPubMed
24.
Zurück zum Zitat Dilek F, Topak N, Aktepe F, Sahin O, Turel KS, Sahin DA, Dilek ON (2008) E-cadherin, β-catenin adhesion complex and relation to matrilysin expression in pT3 rectosigmoid cancers. Pathol Res Practice 204(11):809–815CrossRef Dilek F, Topak N, Aktepe F, Sahin O, Turel KS, Sahin DA, Dilek ON (2008) E-cadherin, β-catenin adhesion complex and relation to matrilysin expression in pT3 rectosigmoid cancers. Pathol Res Practice 204(11):809–815CrossRef
25.
Zurück zum Zitat Tetsuji T, Koji M, Tsuyoshi H (2006) Colorectal cancer: genetics of development and metastasis. J Gastroenterology 41:185–192CrossRef Tetsuji T, Koji M, Tsuyoshi H (2006) Colorectal cancer: genetics of development and metastasis. J Gastroenterology 41:185–192CrossRef
26.
Zurück zum Zitat Ortega P, Moran A, de Juan C, Frias C, Hernandez S, Lopez-Asenjo J-A, Sanchez-Pernaute A, Torres A, Iniesta P, Benito M (2008) Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res 14(4):995–1001CrossRefPubMed Ortega P, Moran A, de Juan C, Frias C, Hernandez S, Lopez-Asenjo J-A, Sanchez-Pernaute A, Torres A, Iniesta P, Benito M (2008) Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res 14(4):995–1001CrossRefPubMed
28.
Zurück zum Zitat McGuire KJ, Qinglang L, Parks CW (2003) Matrilysin (Matrix Metalloproteinase-7) mediates E-Cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162(6):1831–1843PubMed McGuire KJ, Qinglang L, Parks CW (2003) Matrilysin (Matrix Metalloproteinase-7) mediates E-Cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162(6):1831–1843PubMed
Metadaten
Titel
An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1
verfasst von
Zsuzsanna Pap
Zoltán Pávai
Lóránd Dénes
Ilona Kovalszky
János Jung
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9157-x

Weitere Artikel der Ausgabe 4/2009

Pathology & Oncology Research 4/2009 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.